Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Savara Inc chart...

About the Company

savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com

CEO

Robert Neville

Exchange

NASDAQ

Website

http://savarapharma.com/

$5M

Total Revenue

42

Employees

$651M

Market Capitalization

-14.75

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SVRA News

Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update

11d ago, source:

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

Savara Inc. to Participate in Prominent Healthcare Conferences, Casting Spotlight on Future Plans

1mon ago, source: Hosted on MSN

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA), a leading biopharmaceutical company, recently announced its participation in two pivotal investor healthcare conferences in February 2024. The Bucks ...

Savara Inc. Reports Increased Expenses, Anticipates Positive Data from IMPALA-2 Trial

5d ago, source: MyChesCo on MSN

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company, recently reported an increase in both research and development (R&D) and general administrative expenses for the ...

Savara to Present at the Barclays 26th Annual Global Healthcare Conference

12d ago, source:

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced ...

Optimistic Buy Rating for Savara on Molgramostim’s Market Potential and Strong Financials

11d ago, source:

Analyst Jonathan Wolleben of JMP Securities reiterated a Buy rating on Savara (SVRA – Research Report), with a price target of $8.00.

Buy Rating Affirmed: Anticipating IMPALA-2 Trial Success and aPAP Treatment Breakthrough with Molgramostim

8d ago, source:

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Buy rating on Savara (SVRA – Research Report). The associated price target ...

Rick Yang's Net Worth

5d ago, source: Benzinga.com

Inc., Savara Inc, and Korro Bio, Inc.. Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and ...

Savara Inc (YB4P.SG)

27d ago, source: Yahoo Finance

*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Savara Inc. (SVRA)

27d ago, source: Yahoo Finance

*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Savara: Why Sauti Sol had to take a break from each other

7h ago, source: Mpasho News

Delvin Savara Mudigi, one of Sauti Sol, has clarified that they have not disbanded the band, which has been a significant ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...